Medtronic plc (MDT)
| Market Cap | 132.37B |
| Revenue (ttm) | 34.76B |
| Net Income (ttm) | 4.76B |
| Shares Out | 1.28B |
| EPS (ttm) | 3.69 |
| PE Ratio | 27.97 |
| Forward PE | 17.63 |
| Dividend | $2.84 (2.75%) |
| Ex-Dividend Date | Sep 26, 2025 |
| Volume | 13,926,418 |
| Open | 101.53 |
| Previous Close | 101.20 |
| Day's Range | 100.97 - 103.70 |
| 52-Week Range | 79.29 - 103.70 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 108.63 (+5.26%) |
| Earnings Date | Nov 18, 2025 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair produc... [Read more]
Financial Performance
In 2025, Medtronic's revenue was $33.54 billion, an increase of 3.62% compared to the previous year's $32.36 billion. Earnings were $4.66 billion, an increase of 26.82%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for MDT stock is "Buy." The 12-month stock price target is $108.63, which is an increase of 5.26% from the latest price.
News
These Analysts Increase Their Forecasts On Medtronic After Strong Q2 Earnings
Medtronic Plc (NYSE: MDT) on Tuesday reported strong second-quarter 2026 results.
S&P 500 Gains and Losses Today: Home Depot Slumps as Earnings Disappoint; Medtronic Stock Jumps
Shares of a major home improvement retailer lost ground after it missed quarterly profit forecasts, indicating homeowners are putting off remodeling projects amid economic uncertainty. Meanwhile, stro...
Medtronic plc (MDT) Q2 2026 Earnings Call Transcript
Medtronic plc ( MDT) Q2 2026 Earnings Call November 18, 2025 8:00 AM EST Company Participants Ryan Weispfenning - VP & Head of Investor Relations Geoffrey Martha - Chairman of the Board & CEO Thierry...
Medtronic Lifts Outlook as Quarterly Profit, Sales Rise
Medtronic raised its fiscal-year outlook after logging higher profit and sales in its latest quarter, boosted by robust demand across end markets and healthy procedure volumes.
Medtronic Stock Rises After Earnings. What Caught Investors' Attention.
Medtronic exceeds fiscal second-quarter earnings and revenue expectations.
Medtronic beats second-quarter estimates on strength in heart devices segment
Medical device maker Medtronic topped Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by strong demand for its heart disease and diabetes devices.
Medtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum
Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland , Nov. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE...
Top Wall Street Forecasters Revamp Medtronic Expectations Ahead Of Q2 Earnings
Medtronic plc (NYSE: MDT) will release earnings results for the second quarter, before the opening bell on Tuesday, Nov. 18.
Minze Health Announces Collaboration with Medtronic to Support Patients with Overactive Bladder in EMEA
ANTWERP, Belgium--(BUSINESS WIRE)--Minze Health partners with Medtronic to integrate its automated bladder diary, Minze Diary Pod, into Sacral Neuromodulation care for OAB patients.
Medtronic: Possible Earnings Beat Incoming But Still Overvalued
Medtronic plc offers stable dividends and consistent cash flow, but growth remains lackluster with revenues plateauing and limited expansion prospects. MDT's product pipeline, especially in cardiovasc...
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
NEW HOPE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...
Medtronic to announce financial results for its second quarter of fiscal year 2026
GALWAY, Ireland , Nov. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, November 18, 2025,...
Orchestra BioMed to Host Business Update Call on November 12, 2025
NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...
Best Dividend Aristocrats For November 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW...
U.S. Centers for Medicare & Medicaid Services finalizes National Coverage Determination for the Medtronic Symplicity Spyral™ renal denervation (RDN) system
Symplicity blood pressure procedure is now covered for qualifying Medicare patients GALWAY, Ireland , Oct. 28, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology,...
Three-year SPYRAL HTN-ON MED results show sustained, 18 mmHg office-based blood pressure reductions
Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplic...
Medtronic: A Revitalized Dividend Aristocrat To Buy Now
Medtronic's shares have sharply rallied over the last six months. The medtech giant's growth catalysts include a best-in-class product (Affera) in a fast-growing $11 billion space and a massive opport...
It's time to scoop up undervalued stocks in this critical sector of the economy
Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.
Medtronic Stock's $50 Billion Gift To Investors
In the last decade, Medtronic (MDT) stock has returned a notable $52 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let's look at some numbers and compare how this pa...
Medtronic plc - Special Call
Medtronic plc - Special Call Company Participants Ryan Weispfenning - VP & Head of Investor Relations Emily Elswick Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Nathan Tr...
Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions
TIME Best Inventions honors extraordinary innovations changing lives DUBLIN , Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Bra...
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart disease Orchestra BioMed and Medtronic (NYSE:...
Medtronic initiates U.S. IDE clinical study evaluating Hugo™ robotic-assisted surgery system for gynecological procedures
First procedures completed and enrollment underway in Embrace Gynecology study, furthering the company's progress to expand minimally invasive treatment options to patients in the United States GALWAY...
Medtronic Announces Closing of Public Offering of €1.5 Billion of Senior Notes
GALWAY, Ireland , Sept. 29, 2025 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public of...